NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
18.00
+0.90 (5.26%)
At close: Jun 27, 2025, 4:00 PM
17.96
-0.04 (-0.22%)
After-hours: Jun 27, 2025, 5:20 PM EDT
NovoCure Stock Forecast
Stock Price Forecast
The 6 analysts that cover NovoCure stock have a consensus rating of "Buy" and an average price target of $32.83, which forecasts a 82.39% increase in the stock price over the next year. The lowest target is $27 and the highest is $40.
Price Target: $32.83 (+82.39%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for NovoCure stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Reiterates $34 | Buy | Reiterates | $34 | +88.89% | Jun 27, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $42 → $34 | Buy | Maintains | $42 → $34 | +88.89% | Apr 23, 2025 |
| Wedbush | Wedbush | Hold Maintains $29 → $27 | Hold | Maintains | $29 → $27 | +50.00% | Apr 16, 2025 |
| JP Morgan | JP Morgan | Hold Maintains $29 → $28 | Hold | Maintains | $29 → $28 | +55.56% | Apr 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $38 | Strong Buy | Reiterates | $38 | +111.11% | Jan 14, 2025 |
Financial Forecast
Revenue This Year
638.85M
from 605.22M
Increased by 5.56%
Revenue Next Year
697.56M
from 638.85M
Increased by 9.19%
EPS This Year
-1.68
from -1.56
EPS Next Year
-1.83
from -1.68
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 666.7M | 746.9M | 885.6M | ||
| Avg | 638.9M | 697.6M | 796.7M | ||
| Low | 602.7M | 655.3M | 723.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.2% | 16.9% | 27.0% | ||
| Avg | 5.6% | 9.2% | 14.2% | ||
| Low | -0.4% | 2.6% | 3.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.62 | -1.45 | -1.10 | ||
| Avg | -1.68 | -1.83 | -1.48 | ||
| Low | -1.74 | -2.05 | -1.85 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.